The latest results from the RES I trial of Cordis's Nevo drug-eluting stent (DES) indicate that the device is safer than Boston Scientific's Taxus Liberté DES a year after implantation. The results suggest that less stent thrombosis occurs in patients treated with Nevo than with ...
Please Login to read the full article.
